Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

Mohini Rajasagi, Sachet A. Shukla, Edward F. Fritsch, Derin B. Keskin, David DeLuca, Ellese Carmona, Wandi Zhang, Carrie Sougnez, Kristian Cibulskis, John Sidney, Kristen Stevenson, Jerome Ritz, Donna Neuberg, Vladimir Brusic, Stacey Gabriel, Eric S. Lander, Gad Getz, Nir Hacohen, Catherine J. Wu

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Genome sequencing has revealed a large number of shared and personal somatic mutations across human cancers. In principle, any genetic alteration affecting a protein-coding region has the potential to generate mutated peptides that are presented by surface HLA class I proteins that might be recognized by cytotoxic T cells. To test this possibility, we implemented a streamlined approach for the prediction and validation of such neoantigens derived from individual tumors and presented by patient-specific HLA alleles. We applied our computational pipeline to 91 chronic lymphocytic leukemias (CLLs) that underwent whole-exome sequencing (WES). We predicted ~22 mutated HLA-binding peptides per leukemia (derived from ~16 missense mutations) and experimentally confirmed HLA binding for ~55% of such peptides. Two CLL patients that achieved long-term remission following allogeneic hematopoietic stem cell transplantation were monitored for CD8+ T-cell responses against predicted or confirmed HLA-binding peptides. Long-lived cytotoxic T-cell responses were detected against peptides generated from personal tumor mutations in ALMS1, C6ORF89, and FNDC3B presented on tumor cells. Finally, we applied our computational pipeline to WES data (N = 2488 samples) across 13 different cancer types and estimated dozens to thousands of predicted neoantigens per individual tumor, suggesting that neoantigens are frequent in most tumors.

Original languageEnglish
Pages (from-to)453-462
Number of pages10
JournalBlood
Volume124
Issue number3
DOIs
Publication statusPublished - Jul 17 2014
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Tumors
T-cells
Peptides
Neoplasms
Exome
Pipelines
T-Lymphocytes
Stem cells
Mutation
Proteins
Hematopoietic Stem Cell Transplantation
Genes
Missense Mutation
Cells
Open Reading Frames
Leukemia
Alleles
Genome

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Rajasagi, M., Shukla, S. A., Fritsch, E. F., Keskin, D. B., DeLuca, D., Carmona, E., ... Wu, C. J. (2014). Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood, 124(3), 453-462. https://doi.org/10.1182/blood-2014-04-567933

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. / Rajasagi, Mohini; Shukla, Sachet A.; Fritsch, Edward F.; Keskin, Derin B.; DeLuca, David; Carmona, Ellese; Zhang, Wandi; Sougnez, Carrie; Cibulskis, Kristian; Sidney, John; Stevenson, Kristen; Ritz, Jerome; Neuberg, Donna; Brusic, Vladimir; Gabriel, Stacey; Lander, Eric S.; Getz, Gad; Hacohen, Nir; Wu, Catherine J.

In: Blood, Vol. 124, No. 3, 17.07.2014, p. 453-462.

Research output: Contribution to journalArticle

Rajasagi, M, Shukla, SA, Fritsch, EF, Keskin, DB, DeLuca, D, Carmona, E, Zhang, W, Sougnez, C, Cibulskis, K, Sidney, J, Stevenson, K, Ritz, J, Neuberg, D, Brusic, V, Gabriel, S, Lander, ES, Getz, G, Hacohen, N & Wu, CJ 2014, 'Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia', Blood, vol. 124, no. 3, pp. 453-462. https://doi.org/10.1182/blood-2014-04-567933
Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17;124(3):453-462. https://doi.org/10.1182/blood-2014-04-567933
Rajasagi, Mohini ; Shukla, Sachet A. ; Fritsch, Edward F. ; Keskin, Derin B. ; DeLuca, David ; Carmona, Ellese ; Zhang, Wandi ; Sougnez, Carrie ; Cibulskis, Kristian ; Sidney, John ; Stevenson, Kristen ; Ritz, Jerome ; Neuberg, Donna ; Brusic, Vladimir ; Gabriel, Stacey ; Lander, Eric S. ; Getz, Gad ; Hacohen, Nir ; Wu, Catherine J. / Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. In: Blood. 2014 ; Vol. 124, No. 3. pp. 453-462.
@article{4faf80ab6ab3478198088f62f744b8da,
title = "Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia",
abstract = "Genome sequencing has revealed a large number of shared and personal somatic mutations across human cancers. In principle, any genetic alteration affecting a protein-coding region has the potential to generate mutated peptides that are presented by surface HLA class I proteins that might be recognized by cytotoxic T cells. To test this possibility, we implemented a streamlined approach for the prediction and validation of such neoantigens derived from individual tumors and presented by patient-specific HLA alleles. We applied our computational pipeline to 91 chronic lymphocytic leukemias (CLLs) that underwent whole-exome sequencing (WES). We predicted ~22 mutated HLA-binding peptides per leukemia (derived from ~16 missense mutations) and experimentally confirmed HLA binding for ~55{\%} of such peptides. Two CLL patients that achieved long-term remission following allogeneic hematopoietic stem cell transplantation were monitored for CD8+ T-cell responses against predicted or confirmed HLA-binding peptides. Long-lived cytotoxic T-cell responses were detected against peptides generated from personal tumor mutations in ALMS1, C6ORF89, and FNDC3B presented on tumor cells. Finally, we applied our computational pipeline to WES data (N = 2488 samples) across 13 different cancer types and estimated dozens to thousands of predicted neoantigens per individual tumor, suggesting that neoantigens are frequent in most tumors.",
author = "Mohini Rajasagi and Shukla, {Sachet A.} and Fritsch, {Edward F.} and Keskin, {Derin B.} and David DeLuca and Ellese Carmona and Wandi Zhang and Carrie Sougnez and Kristian Cibulskis and John Sidney and Kristen Stevenson and Jerome Ritz and Donna Neuberg and Vladimir Brusic and Stacey Gabriel and Lander, {Eric S.} and Gad Getz and Nir Hacohen and Wu, {Catherine J.}",
year = "2014",
month = "7",
day = "17",
doi = "10.1182/blood-2014-04-567933",
language = "English",
volume = "124",
pages = "453--462",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

AU - Rajasagi, Mohini

AU - Shukla, Sachet A.

AU - Fritsch, Edward F.

AU - Keskin, Derin B.

AU - DeLuca, David

AU - Carmona, Ellese

AU - Zhang, Wandi

AU - Sougnez, Carrie

AU - Cibulskis, Kristian

AU - Sidney, John

AU - Stevenson, Kristen

AU - Ritz, Jerome

AU - Neuberg, Donna

AU - Brusic, Vladimir

AU - Gabriel, Stacey

AU - Lander, Eric S.

AU - Getz, Gad

AU - Hacohen, Nir

AU - Wu, Catherine J.

PY - 2014/7/17

Y1 - 2014/7/17

N2 - Genome sequencing has revealed a large number of shared and personal somatic mutations across human cancers. In principle, any genetic alteration affecting a protein-coding region has the potential to generate mutated peptides that are presented by surface HLA class I proteins that might be recognized by cytotoxic T cells. To test this possibility, we implemented a streamlined approach for the prediction and validation of such neoantigens derived from individual tumors and presented by patient-specific HLA alleles. We applied our computational pipeline to 91 chronic lymphocytic leukemias (CLLs) that underwent whole-exome sequencing (WES). We predicted ~22 mutated HLA-binding peptides per leukemia (derived from ~16 missense mutations) and experimentally confirmed HLA binding for ~55% of such peptides. Two CLL patients that achieved long-term remission following allogeneic hematopoietic stem cell transplantation were monitored for CD8+ T-cell responses against predicted or confirmed HLA-binding peptides. Long-lived cytotoxic T-cell responses were detected against peptides generated from personal tumor mutations in ALMS1, C6ORF89, and FNDC3B presented on tumor cells. Finally, we applied our computational pipeline to WES data (N = 2488 samples) across 13 different cancer types and estimated dozens to thousands of predicted neoantigens per individual tumor, suggesting that neoantigens are frequent in most tumors.

AB - Genome sequencing has revealed a large number of shared and personal somatic mutations across human cancers. In principle, any genetic alteration affecting a protein-coding region has the potential to generate mutated peptides that are presented by surface HLA class I proteins that might be recognized by cytotoxic T cells. To test this possibility, we implemented a streamlined approach for the prediction and validation of such neoantigens derived from individual tumors and presented by patient-specific HLA alleles. We applied our computational pipeline to 91 chronic lymphocytic leukemias (CLLs) that underwent whole-exome sequencing (WES). We predicted ~22 mutated HLA-binding peptides per leukemia (derived from ~16 missense mutations) and experimentally confirmed HLA binding for ~55% of such peptides. Two CLL patients that achieved long-term remission following allogeneic hematopoietic stem cell transplantation were monitored for CD8+ T-cell responses against predicted or confirmed HLA-binding peptides. Long-lived cytotoxic T-cell responses were detected against peptides generated from personal tumor mutations in ALMS1, C6ORF89, and FNDC3B presented on tumor cells. Finally, we applied our computational pipeline to WES data (N = 2488 samples) across 13 different cancer types and estimated dozens to thousands of predicted neoantigens per individual tumor, suggesting that neoantigens are frequent in most tumors.

UR - http://www.scopus.com/inward/record.url?scp=84904472602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904472602&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-04-567933

DO - 10.1182/blood-2014-04-567933

M3 - Article

VL - 124

SP - 453

EP - 462

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -